

Supplementary Fig. 1. GPRC5A post-transcriptionally down-regulates EGFR expression. (a) Plot of the changes in steady state mRNA levels versus changes in corresponding proteins between wild type and *Gprc5a-/-* LBE cells (b) EGFR mRNA turnover rate normalized by GAPDH in wild type and *Gprc5a-/-* LBE cells: real time PCR of EGFR performed in biological triplicate using cDNAs obtained at indicated time points after Actinomycin D (10  $\mu$ g/ml) treatment. (c) Images of IHC staining for GPRC5A in the lung of wild type and *Gprc5a-/-* mice (Scale Bar = 50  $\mu$ m). (d) Detection of expression of the reporter gene LacZ driven by the endogenous Gprc5a promoter in

*Gprc5a-/-* mice using X-gal stain (Scale Bar = 50  $\mu$ m). (e) The relative ratio of EGFR Protein / mRNA (Right) calculated by western blot (Left) and real time PCR (middle) of EGFR in wild type and Gprc5a-/- LBE cells transfected by mock or EGFR siRNA (triplicate) from 3 times independent experiments (Two-tailed Student's t-test, \*\*\* P < 0.001). (f) Western blot of p-EGFR (Y1068), EGFR and  $\beta$ -Actin in wild type and *Gprc5a-/-* LBE cells after EGF treatment at indicated time point. (g) Western blot of EGFR in fractionated wild type and Gprc5a-/- LBE cells, proteins specific to each fraction were detected using integrin  $\alpha V$  (membranes), Tubulin (Cytosol) and Parp (Nucleus). (h) Images of IF for EGFR in *Gprc5a-/-* LBE cells (Scale Bar = 5  $\mu$ m). (i) Left: Western blot of EGFR, GPRC5A and PCNA in H1299 cells stably expressing vector or GPRC5A (C1 and C2 respectively represent Clone 1 and Clone 2). Middle: Real time PCR of EGFR in H1299 cells stably expressing vector or GPRC5A from 3 times independent experiments (Clone 2). Right: The relative ratio of EGFR Protein / mRNA measured by western blot and Real time PCR of EGFR in wild type and Gprc5a-/- LBE cells stably expressing vector or EGFR (Clone 2) from 3 times independent experiments (Student's t-test, \*\*\* P < 0.001). All western blots shown are from a single experiment that is representative of at least 3 biological replicates. All data are mean with s.e.m from biological triplicate.



Supplementary Fig. 2. GPRC5A down-regulates EGFR expression through suppressing translation. (a) EGFR protein degradation rate normalized by  $\beta$ -Actin in wild type and *Gprc5a-/-* LBE cells (Left): Western blot of EGFR and  $\beta$ -Actin in wild type and *Gprc5a-/-* LBE cells after cycloheximide (CHX) (100 µg/ml) treatment at indicated time points (Right). (b) Western blot of EGFR and  $\beta$ -Actin in wild type and *Gprc5a-/-* LBE cells after MG132 (20 ng/ml), Leupeptin (50 µM), NH4Cl (25 mM), Choroquine (20 µM), or Bafilomycin A1 (50 nM) treatment at indicated time points. All western blots were shown are from a single experiment that is representative of at least 3 biological replicates.









b

Supplementary Fig. 3. GPRC5A at ER membrane suppresses EGFR translation. (a) Luciferase assay of wild type and Gprc5a-/- LBE cells expressing psiCHECK<sup>TM</sup>-2 (a luciferase

reporter vector) or psiCHECK<sup>TM</sup>-2-EGFR3'UTR (biological triplicate). (b) Western blot of PeIF2a (Ser51), eIF2a, P-S6 (Ser235/236), S6, P-4E-BP1 (Ser65), P-4E-BP1 (Thr37/46), 4E-BP1, GPRC5A and  $\beta$ -Actin in wild type and *Gprc5a-/-* LBE cells. (c) Co-immunoprecipitation (co-IP) of full length Flag-GPRC5A or the indicated truncations or deletions in H1299 cells. (d) GPRC5A disturbs the binding of eIF4F to cap-agarose in vitro: Add purified Flag-tagged full length GPRC5A or  $\Delta$ (71-190) GPRC5A (protein elution buffer as control) to m<sup>7</sup>GTP-agarose with purified cap-binding proteins from H1299 cells, mix, and wash, following with western blot of eIF4A, eIF4G and eIF4E in the precipitated agarose fraction. (e) GPRC5A binds to eIF4F in vitro: Add purified Flag-tagged full length GPRC5A or  $\Delta$ (71-190) GPRC5A (protein eluted buffer as control) to m<sup>7</sup>GTP-agarose with purified cap-binding proteins from H1299 cells and mix. Then, supernatant was subjected to co-IP of Flag, following with western blot of eIF4G and eIF4E in the precipitated fraction. (f) Alignment of human and mouse GPRC5A. The 71-190 amino acids of GPRC5A, which is the eIF4F interaction region, is shown in the black box. (g) Western blot of GPRC5A in fractionated H1299 cells and wild type LBE cells, proteins specific to each fraction were detected using EGFR (membranes), Tubulin (Cytosol) and Parp (Nucleus). (h) ER Isolation by OptiPrep from mouse wild type LBE cells following western blot of GPRC5A and Calnexin in each fraction. All western blots shown are from a single experiment that is representative of at least 3 biological replicates. All data are mean with s.e.m from biological triplicate.



Supplementary Fig. 4. GPRC5A suppressing EGFR contributes significantly to preventing IR-induced lung tumorigenesis. (a) Antibody arrays: Human Growth Factor antibody arrays from Abcam (Left) and Proteome Profiler Human sReceptor Array from R&D system (Right) of a series well-known secreted growth factor and membrane-bound receptors in H1299 cells stably expressing vector or GPRC5A. The list of up- or down-regulated proteins in H1299 cells stably expressing GPRC5A comparing to H1299 cells stably expressing vector is also shown. (b) Real time PCR of EGFR was performed using cDNAs obtained from wild type and *Gprc5a-/-* mice (5 mice each group) lung tissue at indicated time point after sham irradiation or exposure to 1Gy of X-ray (Two-tailed Student's t-test, \*\* P < 0.01). (c) Images of IHC staining for EGFR in the lung of wild type and *Gprc5a-/-* mice (20 mice each groups) at 1 month after sham irradiation or exposure to 1Gy of X-ray (Scale Bar = 50 µm) (left) and Whisker box plot (Two-tailed Student's

t-test, \*\* P < 0.01) (right). (d) Cell growth curve of wild type and *Gprc5a-/-* LBE cells (Biological triplicate). (e) Top: Western blot of EGFR, GPRC5A and  $\beta$ -Actin in mock siRNA and GPRC5A siRNA transfected Beas2B cells; Bottom: Cell growth curve of mock siRNA and GPRC5A siRNA transfected Beas2B cells (Biological triplicate). (f) Western blot of P-EGFR (Tyr 1068), EGFR, P-MEK1/2 (Ser217/221), MEK1/2, P-Erk1/2 (Ser202/Tyr204), Erk1/2, P-AKT (Ser473), AKT, GPRC5A and  $\beta$ -Actin in cells stably expressing vector or GPRC5A (C1 and C2 respectively represent Clone 1 and Clone 2). (g) Kaplan-Meier survival curve for overall survival of Lung cancer patients with low and high expression of GPRC5A with Log rank test. (Using online Kaplan-Meier Plotter tools: http://kmplot.com/analysis/). All western blots were shown are from a single experiment that is representative of at least 3 biological replicates. All data are mean with s.e.m from biological triplicate.



Supplementary Fig. 5. Uncropped images of immunoblot. Red boxes show cropped regions.



Supplementary Fig. 5. Continued.